Tag: ASX: CSL
Australia’s CSL outlines USD 1.5B plan to boost US plasma therapy manufacturing capacity
Australian biotech firm CSL has announced plans to invest approximately USD 1.5 billion in the United States over the next five years, with the company stating the move is aimed at strengthening domestic manufacturing capacity for plasma-derived therapies.
Featured Article
How AI-enabled cloud ERP is redefining growth for manufacturing leaders
Manufacturing leaders are entering a new phase of supply chain transformation, where growth is increasingly determined by how quickly and intelligently organisations can respond to change.
